Recent research from London has unveiled concerning connections between manufacturing contaminants in adenovirus-associated virus (AAV)-based vectors and liver toxicity observed in gene therapy patients. This investigation sheds light on the potential risks that remain post-manufacturing, particularly in the context of AAV therapies.
Patient Case Study
A pivotal study published earlier this year in a prominent journal highlighted the serious implications of contaminants in AAV-based gene therapies. It details a case involving a pediatric patient who developed acute liver failure shortly after receiving an AAV treatment. This child was being treated for spinal muscular atrophy (SMA) type 1 using onasemnogene abeparvovec (OA), commonly known as Zolgensma, which employs AAV serotype nine (AAV9) to facilitate the expression of the human survival motor neuron (SMN) protein.
Contaminant Discovery
The research team from University College London (UCL) and Great Ormond Street Hospital (GOSH) conducted a thorough analysis of the liver biopsies collected seven weeks post-infusion. They identified fragments of DNA sequences from three plasmids utilized in the manufacturing process. Additionally, incomplete genomes from various AAV serotypes and helper viruses were present. These findings suggest significant contamination during the manufacturing process, potentially contributing to the acute liver toxicity observed in the patient.
Manufacturing Challenges
Zolgensma’s manufacturing process involves transient transfection of the HEK293 cell line using three plasmid components. Two of these components come from AAV, while the third is derived from a helper adenovirus. This method is designed to ensure the final product is free from helper viruses. However, the complexity of this process presents scalability challenges and results in high production costs. Zolgensma is noted for being one of the most expensive drugs globally, with an average cost exceeding $2.1 million per dose.
Implications of Contaminants
In their study, Buddle and Brown documented the presence of multiple AAV serotypes, such as AAV2 and AAV9, along with incomplete DNA fragments from both AAV and helper-virus plasmids in the patient’s liver sample. Contaminants were identified in approximately 5% of the liver cells, indicating that the plasmid DNA had undergone recombination in vivo. The purification processes in place are intended to eliminate unpackaged DNA fragments, which are known to trigger immune responses.
Broader Concerns
The researchers also referenced several preclinical studies where viral plasmid contaminants were detected in liver cells, including observations in non-human primates and human hepatocytes. The pediatric patient in question tested positive for sequences from all three manufacturing plasmids and experienced severe hepatitis following the high-dose infusion of Zolgensma.
Risk of AAV Therapies
Concerns surrounding AAV therapies have intensified following the tragic deaths of patients in clinical trials. Recently, the same AAV strain utilized in Zolgensma was part of Capsida’s CAP-002 therapy, aimed at treating the rare genetic disorder STXBP1. However, this trial is currently on hold after a pediatric patient’s death due to cerebral edema, with the cause not yet determined.
Regulatory Scrutiny
The scrutiny surrounding AAV treatments intensified last year, following the deaths of two non-ambulatory adolescent patients in a clinical trial for Duchenne muscular dystrophy (DMD) and another death linked to a separate trial for limb-girdle muscular dystrophy. These events have raised alarms regarding the safety of AAV-based gene therapies, particularly concerning liver toxicity.
Moving Forward
The findings from this research underscore the critical need for improved manufacturing practices in gene therapy development. Addressing contamination risks is essential to ensure patient safety and the efficacy of these groundbreaking treatments.
Key Takeaways
- AAV-based gene therapies can contain manufacturing contaminants that may lead to liver toxicity.
- A pediatric patient developed acute liver failure post-infusion of Zolgensma, prompting further investigation.
- The complexity of AAV manufacturing processes poses significant challenges, including high costs and potential contamination.
- Regulatory scrutiny surrounding AAV therapies is increasing due to safety concerns and adverse patient outcomes.
In conclusion, the link between manufacturing contaminants and liver toxicity in AAV-based gene therapies raises significant concerns in the field of gene therapy. As the demand for these treatments grows, it will be vital to enhance purification processes and ensure patient safety. The industry must prioritize these issues to maintain public trust and advance therapeutic innovations.
Read more → www.bioprocessintl.com